{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:31:01Z","timestamp":1762867861905,"version":"build-2065373602"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.endien.2022.11.009","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T01:07:44Z","timestamp":1668647264000},"page":"51-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S1","title":["Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high\/very high cardiovascular risk. Consensus document of the Sociedad Espa\u00f1ola de Cardiolog\u00eda [Spanish Society of Cardiology] and the Sociedad Espa\u00f1ola de Diabetes [Spanish Diabetes Society]"],"prefix":"10.1016","volume":"70","author":[{"given":"Juan","family":"Pedro-Botet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivencio","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"S\u00e1nchez-Margalet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Tamargo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Arrieta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 M\u00aa","family":"G\u00e1mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Antonio","family":"Gimeno-Orna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jos\u00e9","family":"G\u00f3mez-Doblas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.endien.2022.11.009_bib0005","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"author":"Instituto Nacional de Estad\u00edstica","key":"10.1016\/j.endien.2022.11.009_bib0010"},{"key":"10.1016\/j.endien.2022.11.009_bib0015","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1161\/CIRCULATIONAHA.118.035289","article-title":"Conceptual framework for addressing residual atherosclerotic cardiovascular disease risk in the era of precision medicine","volume":"137","author":"Patel","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.endien.2022.11.009_bib0020","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/MOL.0000000000000672","article-title":"Reducing residual cardiovascular risk with novel therapies","volume":"31","author":"Davidson","year":"2020","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.endien.2022.11.009_bib0025","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/eurheartj\/ehz767","article-title":"Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies","volume":"41","author":"Lawler","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.endien.2022.11.009_bib0030","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.amjcard.2020.09.043","article-title":"Five-year residual atherosclerotic cardiovascular disease risk prediction model for statin treated patients with known cardiovascular disease","volume":"137","author":"Wong","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.endien.2022.11.009_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2020.107767","article-title":"Diabetes associated residual atherosclerotic cardiovascular risk in statin-treated patients with prior atherosclerotic cardiovascular disease","volume":"35","author":"Zhao","year":"2021","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.endien.2022.11.009_bib0040","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.jacc.2016.09.928","article-title":"Determining when to add nonstatin therapy: a quantitative approach","volume":"68","author":"Robinson","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.endien.2022.11.009_bib0045","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"Scandinavian Simvastatin Survival Study group","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.endien.2022.11.009_bib0050","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2022.11.009_bib0055","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2022.11.009_bib0060","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","author":"Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2022.11.009_bib0065","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.endien.2022.11.009_bib0070","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.endien.2022.11.009_bib0075","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.endien.2022.11.009_bib0080","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.endien.2022.11.009_bib0085","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2022.11.009_bib0090","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","article-title":"HOPE-3 Investigators. Cholesterol lowering in intermediate-risk persons without cardiovascular disease","volume":"374","author":"Yusuf","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2022.11.009_bib0095","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2022.11.009_bib0100","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2022.11.009_bib0105","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2022.11.009_bib0110","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0140-6736(10)60545-4","article-title":"Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.endien.2022.11.009_bib0115","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies \u2014 a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.endien.2022.11.009_bib0120","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/clinchem\/hvaa252","article-title":"Residual cardiovascular risk at low LDL: remnants, lipoprotein(a), and inflammation","volume":"67","author":"Hoogeveen","year":"2021","journal-title":"Clin Chem"},{"key":"10.1016\/j.endien.2022.11.009_bib0125","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.endien.2022.11.009_bib0130","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/dom.13537","article-title":"Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol","volume":"21","author":"Nichols","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.endien.2022.11.009_bib0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2020.100087","article-title":"Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: results from National Health and Nutrition Examination Survey (NHANES) 2007\u20132014","volume":"3","author":"Fan","year":"2020","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.endien.2022.11.009_bib0140","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/MED.0000000000000530","article-title":"Triglycerides and residual risk","volume":"27","author":"Vallejo-Vaz","year":"2020","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.endien.2022.11.009_bib0145","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1016\/j.jacc.2021.04.059","article-title":"Triglycerides and residual atherosclerotic risk","volume":"77","author":"Raposeiras-Roubin","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.endien.2022.11.009_bib0150","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","article-title":"PROVE IT-TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial","volume":"51","author":"Miller","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.endien.2022.11.009_bib0155","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"AIM-HIGH Investigators","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2022.11.009_bib0160","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2022.11.009_bib0165","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.endien.2022.11.009_bib0170","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"ACCORD Study Group","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2022.11.009_bib0175","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.endien.2022.11.009_bib0180","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMc1006407","article-title":"Combination lipid therapy in type 2 diabetes","volume":"363","author":"Sacks","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2022.11.009_bib0185","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/FJC.0b013e318202709f","article-title":"Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis","volume":"57","author":"Bruckert","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.endien.2022.11.009_bib0190","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.atherosclerosis.2011.04.020","article-title":"Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis","volume":"217","author":"Lee","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.endien.2022.11.009_bib0195","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","article-title":"Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study","volume":"206","author":"Pradhan","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.endien.2022.11.009_bib0200","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1203859","article-title":"The ORIGIN Trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia","volume":"367","author":"Bosch","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2022.11.009_bib0205","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","article-title":"The ASCEND Study Collaborative Group. Effects of n-3 fatty acid supplements in diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2022.11.009_bib0210","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1811403","article-title":"VITAL Research Group. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer","volume":"380","author":"Manson","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2022.11.009_bib0215","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.endien.2022.11.009_bib0220","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamacardio.2017.5205","article-title":"Omega-3 Treatment Trialists\u2019 Collaboration. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 individuals","volume":"3","author":"Aung","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.endien.2022.11.009_bib0225","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"author":"European Medicines Agency","key":"10.1016\/j.endien.2022.11.009_bib0230"},{"key":"10.1016\/j.endien.2022.11.009_bib0235","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC Scientific Document Group. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.endien.2022.11.009_bib0240","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2021.03.039","article-title":"Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: a statement from a European Atherosclerosis Society Task Force","volume":"325","author":"Averna","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.endien.2022.11.009_bib0245","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.endien.2022.11.009_bib0250","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jacl.2019.10.014","article-title":"National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk","volume":"13","author":"Orringer","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.endien.2022.11.009_bib0255","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC Expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"78","author":"Virani","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.endien.2022.11.009_bib0260","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.2337\/dc22-S010","article-title":"Cardiovascular disease and risk management: standards of medical care in diabetes\u20142022","volume":"45","author":"American Diabetes Association","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endien.2022.11.009_bib0265","first-page":"1129","article-title":"2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.endien.2022.11.009_bib0270","doi-asserted-by":"crossref","first-page":"J34","DOI":"10.1093\/eurheartj\/suaa117","article-title":"Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies","volume":"22","author":"Olshansky","year":"2020","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.endien.2022.11.009_bib0275","article-title":"n-3 fatty acids and serum lipoproteins: human studies","volume":"65","author":"Harris","year":"1997","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.endien.2022.11.009_bib0280","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1080\/00325481.2017.1385365","article-title":"Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?","volume":"129","author":"Nelson","year":"2017","journal-title":"Postgrad Med"},{"key":"10.1016\/j.endien.2022.11.009_bib0285","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/ATVBAHA.119.313286","article-title":"Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid","volume":"40","author":"Mason","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.endien.2022.11.009_bib0290","series-title":"Omega-3 Fatty Acids","first-page":"541","article-title":"Pharmacokinetics and safety profile of omega-3 polynsaturated fatty acids","author":"Tamargo","year":"2016"},{"key":"10.1016\/j.endien.2022.11.009_bib0295","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/07853890.2018.1511919","article-title":"Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials","volume":"50","author":"Sahebkar","year":"2018","journal-title":"Ann Med"},{"key":"10.1016\/j.endien.2022.11.009_bib0300","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/FJC.0000000000000379","article-title":"Eicosapentaenoic acid inhibits oxidation of apoB-containing lipoprotein particles of different size in vitro when administered alone or in combination with atorvastatin active metabolite compared with other triglyceride-lowering agents","volume":"68","author":"Mason","year":"2016","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.endien.2022.11.009_bib0305","doi-asserted-by":"crossref","first-page":"J3","DOI":"10.1093\/eurheartj\/suaa115","article-title":"Mechanistic insights into cardiovascular protection for omega-3 fatty acids and their bioactive lipid metabolites","volume":"22","author":"O\u2019Connell","year":"2020","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.endien.2022.11.009_bib0310","doi-asserted-by":"crossref","first-page":"432","DOI":"10.2174\/157016112800812845","article-title":"Omega-3 fatty acids and HDL. How do they work in the prevention of cardiovascular disease?","volume":"10","author":"Burillo","year":"2012","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.endien.2022.11.009_bib0315","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/5584_2020_479","article-title":"Glucose lowering efficacy and pleiotropic effects of sodium-glucose cotransporter 2 inhibitors","volume":"1307","author":"Kuchay","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.endien.2022.11.009_bib0320","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.jacc.2011.06.063","article-title":"Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events","volume":"58","author":"Mozaffarian","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.endien.2022.11.009_bib0325","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/ajcn\/84.1.5","article-title":"n\u22123 fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review","volume":"84","author":"Wang","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.endien.2022.11.009_bib0330","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mayocp.2016.10.018","article-title":"A meta-analysis of randomized controlled trials and prospective cohort studies of eicosapentaenoic and docosahexaenoic long-chain omega-3 fatty acids and coronary heart disease risk","volume":"92","author":"Alexander","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.endien.2022.11.009_bib0335","article-title":"Omega-3 Treatment Trialists\u2019 Collaboration. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease","volume":"29","author":"Abdelhamid","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.endien.2022.11.009_bib0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100997","article-title":"Effect of omega-3 fatty acids on cardiovascular outcomes: a systematic review and meta-analysis","volume":"38","author":"Khan","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.endien.2022.11.009_bib0345","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(99)07072-5","article-title":"Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell\u2019Infarto miocardico","volume":"354","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.endien.2022.11.009_bib0350","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.endien.2022.11.009_bib0355","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2008.06.003","article-title":"JELIS Investigators, Japan. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)","volume":"200","author":"Saito","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.endien.2022.11.009_bib0360","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5551\/jat.5876","article-title":"JELIS Investigators. Relationships between plasma fatty acid composition and coronary artery disease","volume":"18","author":"Itakura","year":"2011","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.endien.2022.11.009_bib0365","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.prostaglandins.2016.07.007","article-title":"Icosapent ethyl: eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies","volume":"125","author":"Bays","year":"2016","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.endien.2022.11.009_bib0370","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jjcc.2017.07.007","article-title":"CHERRY study investigators. A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins","volume":"70","author":"Watanabe","year":"2017","journal-title":"J Cardiol"},{"key":"10.1016\/j.endien.2022.11.009_bib0375","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl. Reply","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2022.11.009_bib0380","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/eurheartj\/ehz179","article-title":"REDUCE-IT","volume":"40","author":"Bhatt","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.endien.2022.11.009_bib0385","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.jacc.2019.02.032","article-title":"REDUCE-IT Investigators. Effects of icosapent ethyl on total ischemic events: from REDUCE-IT","volume":"73","author":"Bhatt","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.endien.2022.11.009_bib0390","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.jacc.2019.06.043","article-title":"REDUCE-IT Investigators. Reduction in first and total ischemic events with icosapent ethyl across baseline triglyceride tertiles","volume":"74","author":"Bhatt","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.endien.2022.11.009_bib0395","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1161\/CIRCULATIONAHA.120.050276","article-title":"REDUCE-IT Investigators. Reduction in revascularization with icosapent ethyl: insights from REDUCE-IT Revascularization analyses","volume":"143","author":"Peterson","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.endien.2022.11.009_bib0400","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1161\/CIRCULATIONAHA.121.055560","article-title":"Benefits of icosapent ethyl across the range of kidney function in patients with established cardiovascular disease or diabetes: REDUCE-IT RENAL","volume":"144","author":"Majithia","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.endien.2022.11.009_bib0405","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1161\/CIRCULATIONAHA.121.056290","article-title":"REDUCE-IT Investigators. Icosapent ethyl reduces ischemic events in patients with a history of previous coronary artery bypass grafting: REDUCE-IT CABG","volume":"144","author":"Verma","year":"2021","journal-title":"Circulation"},{"year":"2020","series-title":"Icosapent ethyl provides consistent cardiovascular benefit in patients with diabetes in REDUCE-IT","author":"Bhatt","key":"10.1016\/j.endien.2022.11.009_bib0410"},{"key":"10.1016\/j.endien.2022.11.009_bib0415","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehaa652","article-title":"Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial","volume":"41","author":"Budoff","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.endien.2022.11.009_bib0420","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jacc.2018.10.066","article-title":"Coronary artery plaque characteristics associated with adverse outcomes in the SCOT-HEART study","volume":"73","author":"Williams","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.endien.2022.11.009_bib0425","unstructured":"Vaskepa. Ficha t\u00e9cnica o resumen de las caracter\u00edsticas del producto. [Accessed 20 November 2021]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vazkepa-epar-product-information_es.pdf."},{"key":"10.1016\/j.endien.2022.11.009_bib0430","unstructured":"UMIN-CTR Clinical Trial. Randomized trial for evaluation in secondary prevention efficacy of combination therapy \u2014 statin and eicosapentaenoic acid. April 27, 2018. [Accessed 9 December 2021]. Available from: https:\/\/upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000014051."},{"key":"10.1016\/j.endien.2022.11.009_bib0435","first-page":"128","article-title":"Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Society of Arteriosclerosis (SEA), 2019","volume":"31","author":"Ascaso","year":"2019","journal-title":"Clin Investig Arterioscler"},{"key":"10.1016\/j.endien.2022.11.009_bib0440","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Heart Outcomes Prevention Evaluation Study Investigators","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2022.11.009_bib0445","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2022.11.009_bib0450","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/j.amjmed.2020.12.023","article-title":"Icosapent ethyl for primary versus secondary prevention of major adverse cardiovascular events in hypertriglyceridemia: value for money analysis","volume":"134","author":"Arbel","year":"2021","journal-title":"Am J Med"},{"key":"10.1016\/j.endien.2022.11.009_bib0455","unstructured":"Instituto Nacional de Estad\u00edstica. Estad\u00edstica del Padr\u00f3n Continuo. Datos provisionales a 1 de enero de 2021. [Accessed 9 December 2021]. Available from: https:\/\/www.ine.es\/jaxi\/Datos.htm?path=\/t20\/e245\/p04\/provi\/l0\/&file=00000003.px#!tabs-tabla."},{"key":"10.1016\/j.endien.2022.11.009_bib0460","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijcard.2021.08.031","article-title":"Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: an analysis of the REduction of Atherothrombosis for Continued Health (REACH) registry","volume":"340","author":"Picard","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.endien.2022.11.009_bib0465","first-page":"197","article-title":"en nombre del Grupo de investigaci\u00f3n del Estudio SIMETAP. Population and methodology of the SIMETAP study: prevalence of cardiovascular risk factors, cardiovascular diseases, and related metabolic diseases","volume":"30","author":"Ruiz-Garc\u00eda","year":"2018","journal-title":"Clin Investig Arterioscler"},{"key":"10.1016\/j.endien.2022.11.009_bib0470","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s00125-011-2336-9","article-title":"Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study","volume":"55","author":"Soriguer","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.endien.2022.11.009_bib0475","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1093\/eurjpc\/zwaa073","article-title":"Half of patients with type 2 diabetes mellitus are at very high cardiovascular risk according to the ESC\/EASD: data from a large Mediterranean population","volume":"28","author":"Cebri\u00e1n-Cuenca","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.endien.2022.11.009_bib0480","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.endien.2022.11.009_bib0485","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.amjcard.2020.08.015","article-title":"REDUCE-IT eligibility and preventable cardiovascular events in the US population (from the National Health and Nutrition Examination Survey [NHANES])","volume":"134","author":"Wong","year":"2020","journal-title":"Am J Cardiol"}],"container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530018022001676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530018022001676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:17:16Z","timestamp":1762867036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2530018022001676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":97,"alternative-id":["S2530018022001676"],"URL":"https:\/\/doi.org\/10.1016\/j.endien.2022.11.009","relation":{},"ISSN":["2530-0180"],"issn-type":[{"type":"print","value":"2530-0180"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high\/very high cardiovascular risk. Consensus document of the Sociedad Espa\u00f1ola de Cardiolog\u00eda [Spanish Society of Cardiology] and the Sociedad Espa\u00f1ola de Diabetes [Spanish Diabetes Society]","name":"articletitle","label":"Article Title"},{"value":"Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.endien.2022.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.endinu.2022.03.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 SEEN and SED. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}